Lilly (Eli) vs Pfizer
Lilly (Eli) and Pfizer are similar in size: $65.18bn and $62.58bn of revenue in their latest fiscal years. Lilly (Eli) grew faster (44.7% against -1.6%). Lilly (Eli) kept more of each dollar of sales as profit: a net margin of 31.7% against 12.4%.
| Latest fiscal year | Lilly (Eli)LLY, 2025 | PfizerPFE, 2025 |
|---|---|---|
| Revenue | $65.18bn | $62.58bn |
| Revenue growth | 44.7% | -1.6% |
| Net income | $20.64bn | $7.77bn |
| Operating margin | — | — |
| Net margin | 31.7% | 12.4% |
| Return on equity | 101.2% | 8.9% |
| Free cash flow | $8.97bn | $9.07bn |
| Cash | $7.27bn | $1.14bn |
| Total debt | $42.50bn | $64.80bn |
| Debt to equity | 160.2% | — |
| Dividend per share | $6.23 | $1.72 |
| Dividend yield | 0.5% | 5.5% |
| Share buybacks | $4.11bn | — |
| Employees | 50,000 | 75,000 |
| Market value | $1.26tn | $174.79bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 78 (Strong) | 78 (Strong) |
| Insider trades, 12 months | 0 buys, 240 sales | 3 buys, 2 sales |